ProShare Advisors’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-659
| Closed | -$9.54K | – | 2099 |
|
|
2024
Q2 | $9.54K | Sell |
659
-225
| -25% | -$3.75K | ﹤0.01% | 1837 |
|
|
2024
Q1 | $13.7K | Buy |
884
+79
| +10% | +$1.7K | ﹤0.01% | 1987 |
|
|
2023
Q4 | $22.5K | Sell |
805
-246
| -23% | -$6.46K | ﹤0.01% | 1914 |
|
|
2023
Q3 | $50K | Buy |
1,051
+5
| +0.5% | +$382 | ﹤0.01% | 1715 |
|
|
2023
Q2 | $100K | Buy |
1,046
+199
| +23% | +$21.7K | ﹤0.01% | 1697 |
|
|
2023
Q1 | $96K | Sell |
847
-122
| -13% | -$13.2K | ﹤0.01% | 1598 |
|
|
2022
Q4 | $108K | Buy |
969
+59
| +6% | +$7.91K | ﹤0.01% | 1635 |
|
|
2022
Q3 | $117K | Buy |
910
+155
| +21% | +$15.9K | ﹤0.01% | 1530 |
|
|
2022
Q2 | $52K | Sell |
755
-373
| -33% | -$32.1K | ﹤0.01% | 1699 |
|
|
2022
Q1 | $161K | Sell |
1,128
-277
| -20% | -$42.6K | ﹤0.01% | 1937 |
|
|
2021
Q4 | $234K | Sell |
1,405
-21
| -1% | -$3.34K | ﹤0.01% | 1932 |
|
|
2021
Q3 | $198K | Sell |
1,426
-300
| -17% | -$58.7K | ﹤0.01% | 1799 |
|
|
2021
Q2 | $824K | Buy |
1,726
+357
| +26% | +$151K | ﹤0.01% | 1152 |
|
|
2021
Q1 | $564K | Buy |
1,369
+53
| +4% | +$24.4K | ﹤0.01% | 1355 |
|
|
2020
Q4 | $645K | Buy |
1,316
+271
| +26% | +$159K | ﹤0.01% | 1109 |
|
|
2020
Q3 | $592K | Buy |
1,045
+166
| +19% | +$55.2K | ﹤0.01% | 883 |
|
|
2020
Q2 | $84K | Buy |
879
+290
| +49% | +$25.4K | ﹤0.01% | 1589 |
|
|
2020
Q1 | $42K | Sell |
589
-415
| -41% | -$27.8K | ﹤0.01% | 1126 |
|
|
2019
Q4 | $69K | Sell |
1,004
-150
| -13% | -$11.1K | ﹤0.01% | 1730 |
|
|
2019
Q3 | $93K | Buy |
1,154
+445
| +63% | +$29.4K | ﹤0.01% | 1559 |
|
|
2019
Q2 | $46K | Sell |
709
-97
| -12% | -$9.21K | ﹤0.01% | 1576 |
|
|
2019
Q1 | $111K | Buy |
806
+5
| +0.6% | +$610 | ﹤0.01% | 1561 |
|
|
2018
Q4 | $72K | Sell |
801
-157
| -16% | -$22K | ﹤0.01% | 1507 |
|
|
2018
Q3 | $145K | Sell |
958
-32
| -3% | -$5.18K | ﹤0.01% | 1643 |
|
|
2018
Q2 | $170K | Sell |
990
-78
| -7% | -$12.7K | ﹤0.01% | 1643 |
|
|
2018
Q1 | $157K | Sell |
1,068
-176
| -14% | -$33.8K | ﹤0.01% | 1583 |
|
|
2017
Q4 | $252K | Buy |
1,244
+33
| +3% | +$6.78K | ﹤0.01% | 1512 |
|
|
2017
Q3 | $389K | Buy |
1,211
+84
| +7% | +$23K | ﹤0.01% | 1053 |
|
|
2017
Q2 | $255K | Sell |
1,127
-53
| -4% | -$10.9K | ﹤0.01% | 1244 |
|
|
2017
Q1 | $266K | Sell |
1,180
-296
| -20% | -$60.1K | ﹤0.01% | 1292 |
|
|
2016
Q4 | $292K | Buy |
1,476
+120
| +9% | +$26.2K | ﹤0.01% | 1379 |
|
|
2016
Q3 | $333K | Sell |
1,356
-224
| -14% | -$78.6K | ﹤0.01% | 1111 |
|
|
2016
Q2 | $918K | Buy |
1,580
+82
| +5% | +$48.1K | 0.01% | 748 |
|
|
2016
Q1 | $796K | Sell |
1,498
-135
| -8% | -$70.5K | 0.01% | 797 |
|
|
2015
Q4 | $1.15M | Buy |
+1,633
| New | +$1.07M | 0.01% | 684 |
|
Other funds holding MCRB
FP
SSA
ProShare Advisors's MCRB Position: Q3 2024 in Review
ProShare Advisors sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 659 shares — an estimated $9.54K sold.
ProShare Advisors first reported a position in MCRB in Q4 2015 and held it in 35 quarters. The position peaked at $1.15M in Q4 2015. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.
- ProShare Advisors reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
- ProShare Advisors sold 659 Seres Therapeutics shares in Q3 2024, an estimated $9.54K.
- ProShare Advisors first reported a position in Seres Therapeutics in Q4 2015 and held it in 35 quarters.
- ProShare Advisors's Seres Therapeutics position peaked at $1.15M in Q4 2015.
- 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.
Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.